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TNF is a well-characterized proinflammatory 
cytokine with a critical role in the pathogenesis 
of various inflammatory diseases (Eigler et al., 
1997). The importance of TNF in the initia-
tion of inflammatory disorders is particularly 
obvious in inflammatory bowel disease (IBD), 
such as Crohn’s disease and ulcerative colitis, 
where unrestrained reactions against luminal 
antigens and commensal bacteria result in devas-
tating inflammatory responses in the intestinal 
mucosa. TNF is rapidly induced in the intesti-
nal mucosa upon initial activation of immune 
cells and seems to be important for the further 
acceleration  of  the  inflammatory  response. 
Consequently, absence or inhibition of TNF 
activity ameliorates disease progression in dif-
ferent experimental IBD models and human 
patients (Neurath et al., 1997; Corazza et al., 
1999; Papadakis and Targan, 2000).
Apart  from  its  well-characterized  proin-
flammatory role, there is increasing evidence 
for  various  antiinflammatory  properties  of 
TNF. For example, although TNF is critical 
for the initiation of experimental autoimmune 
encephalomyelitis, it is also involved in the res-
olution  of  the  disease  (Kassiotis  and  Kollias, 
2001). Similar observations have been made in 
dextran sodium sulfate (DSS)–induced colitis, 
where the absence or neutralization of TNF 
leads to an exacerbation of disease (Naito et al., 
2003). These antiinflammatory properties of 
TNF may be attributed at least in part to its 
apoptosis-modulating  activities  in  immune   
cells (Zheng et al., 1995). In particular, TNF 
strongly sensitizes T cells to apoptosis induc-
tion, resulting in an accelerated resolution of 
the inflammatory response (Zhou et al., 1996). 
Although the antiinflammatory effects of TNF 
on activated T cells are well described, little is 
known about its immunosuppressive activity in 
nonimmune cells.
Glucocorticoids  (GCs)  are  steroid  hor-
mones with potent antiinflammatory properties 
(Riccardi et al., 2002). Thus, a variety of in-
flammatory disorders are successfully treated 
with GCs. Endogenous GCs are predominantly 
produced in the adrenal glands in response to 
emotional, physical, and immunological stress. 
Consequently, removal of the adrenal glands 
or pharmacological inhibition of systemic GC 
synthesis may result in shock or death after in-
duction of a strong immune response (Gonzalo 
et al., 1993). Over the last decade, there has 
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Although tumor necrosis factor () (TNF) exerts proinflammatory activities in a variety of 
diseases, including inflammatory bowel disease, there is increasing evidence for antiinflam-
matory actions of TNF. In contrast, glucocorticoids (GCs) are steroid hormones that  
suppress inflammation, at least in part by regulating the expression and action of TNF. We 
report that TNF induces extraadrenal production of immunoregulatory GCs in the intestinal 
mucosa during acute intestinal inflammation. The absence of TNF results in a lack of  
colonic GC synthesis and exacerbation of dextran sodium sulfate–induced colitis. TNF seems 
to promote local steroidogenesis by directly inducing steroidogenic enzymes in intestinal 
epithelial cells. Therapeutic administration of TNF induces GC synthesis in oxazolone-
induced colitis and ameliorates intestinal inflammation, whereas inhibition of intestinal GC 
synthesis abrogates the therapeutic effect of TNF. These data show that TNF suppresses the 
pathogenesis of acute intestinal inflammation by promoting local steroidogenesis.
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of all clinical parameters and reduced inflammation. These 
data define a novel antiinflammatory role of TNF by induc-
ing local GC synthesis in the intestinal mucosa.
RESULTS
DSS colitis–induced expression of steroidogenic enzymes 
and synthesis of intestinal GCs
To investigate whether the induction of acute intestinal in-
flammation affects intestinal GC synthesis, we used different 
well-characterized models of chemically induced colitis. A 
common feature of chemically induced colitides appears to 
be an initial disruption of the epithelial cell barrier that pro-
motes increased immune cell exposure to constituents of the 
luminal microflora. To this date many different mouse mod-
els of mucosal inflammation have been characterized, which 
allows us to investigate various aspects of the pathogenesis 
operative also in patients with IBD (Strober et al., 2002). We 
have previously shown that the absence of LRH-1 exacer-
bates TNBS-induced colitis (Coste et al., 2007), likely be-
cause of the lack of colonic GC synthesis. As TNBS colitis is 
T cell dependent and characterized by a typical (Th1) cyto-
kine pattern, we aimed at investigating intestinal GC synthe-
sis in T cell–dependent and –independent models of colitis, 
as well as colitis mediated by either a Th1- or Th2-type T 
cell response.
We initially used the DSS model as a model for T cell– 
independent intestinal inflammation by feeding animals with 
3% DSS in the drinking water. As DSS colitis can also be in-
duced in animals lacking T and B cells (Strober et al., 2002), 
the adaptive immune system obviously plays a minor role in 
this model, at least in the acute phase. Inflammation is largely 
driven by activated nonlymphoid cells, such as macrophages 
and neutrophils, and associated release of proinflammatory 
cytokines such as TNF (Dieleman et al., 1994). Hence, 
induction of acute DSS colitis is particularly useful to study 
the contribution of innate immune mechanisms. DSS-mediated 
intestinal inflammation was characterized by extensive epi-
thelial erosion, loss of goblet cells, and strong leukocytic in-
filtration of the colonic mucosa of diseased animals (Fig. 1, 
A and B), and was associated with clinical parameters such   
as weight loss (Fig. 1 C) and colon shortening (Fig. 1 D).   
Simultaneously, increased expression levels of the Th1-type 
cytokines TNF and IFN- were observed in colonic tissue 
samples of DSS-treated animals (Fig. 1, E and F).
GC synthesis is critically regulated by the expression of 
steroidogenic enzymes. In particular, the rate-limiting enzyme 
P450scc, encoded by the CYP11A1 gene, converts choles-
terol to pregnenolone, and 11-hydroxylase (P450C11), en-
coded by the CYP11B1 gene, converts 11-deoxycorticosterone 
to active corticosterone. Induction of DSS colitis resulted 
in a profound and significant increase in the expression of 
CYP11A1 (Fig. 1 G) and CYP11B1 (Fig. 1 H). Furthermore, 
in ex vivo organ cultures of colonic tissue from DSS-treated 
mice, we observed a sharp and strong increase in corticoste-
rone synthesis, with peak production at day 7 and a subse-
quent decrease thereafter (Fig. 1 I). The observed GC synthesis 
been accumulating evidence that synthesis of bioactive GCs 
is not restricted to the adrenal glands but extends to other 
extraadrenal sources, such as the thymus, brain, skin, and vas-
cular endothelium (Davies and MacKenzie, 2003). Yet, in most 
situations the function of this extraadrenal GC production   
is unknown.
We have recently shown, however, that the intestinal 
mucosa is a potent extraadrenal source of GCs, and that local 
GCs contribute to the maintenance of intestinal immune ho-
meostasis by controlling the activation of intestinal T lym-
phocytes (Cima et al., 2004). The major source of intestinal 
GCs appears to be the proliferating and undifferentiated epi-
thelial cells of the crypts (Cima et al., 2004; Atanasov et al., 
2008). Interestingly, the molecular control of adrenal and 
intestinal GC synthesis seems to be fundamentally different. 
Although the nuclear receptor and transcription factor ste-
roidogenic factor–1/NR5A1 is essential for the expression of 
steroid-producing enzymes of the cytochrome P450 family 
in the adrenal cortex (Parker et al., 2002), it is absent in the 
intestinal mucosa and seems to be functionally replaced by 
the close homologue liver receptor homologue–1/NR5A2 
(LRH-1; Mueller et al., 2006, 2007). Consequently, LRH-1 
deficiency in the intestinal epithelium leads to defective 
expression of steroidogenic enzymes and intestinal GC syn-
thesis (Mueller et al., 2006). Interestingly, this lack of local 
GC synthesis also correlates with an increased susceptibil-
ity of LRH-1–deficient mice to experimentally induced 
colitis (Coste et al., 2007). Furthermore, a potentially critical 
role for LRH-1 and intestinal GC synthesis in the control of 
IBD is supported by the observation that LRH-1 and ste-
roidogenic enzymes are expressed at reduced levels at sites of 
intestinal inflammation in patients with Crohn’s disease and 
ulcerative colitis (Coste et al., 2007).
In this study, we aimed at investigating the relationship 
between acute intestinal inflammation, TNF, and intestinal 
GC synthesis. We show that experimentally induced colitis 
promotes up-regulation of steroidogenic enzymes and the 
synthesis of intestinal GCs. Notably, the induction of GC 
synthesis does not seem to depend on the inflammation per 
se but on the type of inflammation. Intestinal GC synthesis 
was induced by Th1-type inflammation initiated by the hap-
ten 2,4,6-trinitrobenzenesulphonic acid (TNBS) and DSS, 
but not by the Th2-type inflammation–promoting hapten 
oxazolone. TNF was found to be a key factor in the regula-
tion of intestinal GC synthesis, as absence of TNF resulted 
in an almost complete lack of steroidogenic enzyme expression 
and intestinal GC synthesis. Importantly, DSS-induced colitis 
in the absence of TNF resulted in reduced intestinal GC syn-
thesis with simultaneous exacerbation of disease, suggesting 
an antiinflammatory role of TNF-induced GC synthesis in 
the pathogenesis of DSS colitis. Injection of TNF alone was 
sufficient to trigger intestinal GC synthesis, and stimulation 
of intestinal epithelial cells with TNF directly induced the 
expression of steroidogenic enzymes. Finally, repetitive ad-
ministration of TNF restored colonic GC synthesis during 
oxazolone-induced colitis and resulted in an amelioration JEM VOL. 207, May 10, 2010 
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was bona fide in situ produced, as it was blockable with 
metyrapone, a potent inhibitor of 11-hydroxylase and GC 
synthesis (Sprunt and Hannah, 1968).
TNBS induces a Th1-type colitis and intestinal GC synthesis
We next assessed intestinal GC synthesis in TNBS-induced 
colitis representing an acute T cell–dependent model of intes-
tinal inflammation. Rectal administration of the haptenizing 
agent TNBS resulted in a Th1-mediated colonic inflamma-
tion characterized by infiltration of colitogenic CD4+ T cells 
(Neurath et al., 2000), destruction of the colonic epithelium 
(Fig. 2 B), rapid weight loss (Fig. 2 C), and shortening of   
the colon (Fig. 2 D). These parameters were only transiently   
observed in control-treated animals. In agreement with a Th1 
type of inflammation, TNF and IFN- expression were in-
creased in diseased but not control animals (Fig. 2, E and F), 
with undetectable levels of the Th2 cytokine IL-4 (not de-
picted). Comparable to DSS colitis, we observed a substantial 
increase in the expression levels of the steroidogenic enzymes 
CYP11A1 (Fig. 2 G) and CYP11B1 (Fig. 2 H), and the 
induction of metyrapone-blockable corticosterone synthesis 
(Fig. 2 I). No induction of colonic steroidogenesis was ob-
served in control-treated animals. These data indicate that the 
induction of experimental colitis results in intestinal GC syn-
thesis as a way to counterbalance colonic inflammation.
Oxazolone-induced Th2-type colitis does not promote 
intestinal GC synthesis
Various animal models of colitis are characterized with differ-
ent types of polarized T cell responses. Although TNBS in-
duces a profound Th1 type of inflammation, administration of 
the haptenizing agent oxazolone results in a profound and 
acute intestinal inflammation caused by a polarized Th2 T cell 
response (Strober et al., 2002). Treatment of sensitized mice 
by rectal application of oxazolone in 50% ethanol resulted in 
rapid weight loss (Fig. 3 C) and colon shortening (Fig. 3 D) 
because of massive inflammation of the colonic tissue (Fig. 3 B). 
This inflammatory response was characterized by a strong 
increase in the Th2 cytokine IL-4 (Fig. 3 F), whereas no 
increase in the Th1 cytokines TNF (Fig. 3 E) or IFN- (not 
depicted) was observed. Surprisingly, although TNBS- and 
oxazolone-induced colitis had a similar kinetic of weight loss 
and colon shortening, and the overall inflammation-induced 
tissue destruction was comparable, absolutely no increase in 
the expression of the steroidogenic enzymes CYP11A1 and 
CYP11B1 was observed in colonic tissue of oxazolone-treated 
mice (Fig. 3, G and H). Interestingly, we even observed a 
slight but significant decrease in CYP11A1 expression in the 
colonic tissue of oxazolone- versus control-treated animals. In 
agreement with the absence of induction of the steroidogenic 
enzymes CYP11A1 and CYP11B1, no increase in intestinal 
GC synthesis was observed. These data suggest that an acute 
Th1 type of colonic inflammation promotes intestinal GC 
synthesis, whereas a Th2 type of response fails to do so.
TNF but not colonic inflammation is required  
for colitis-induced intestinal GC synthesis
The results described in the previous section demonstrate that 
intestinal GC synthesis depends on the type of inflammation 
and not the inflammatory process per se. A major difference 
Figure 1.  DSS-induced colitis and intestinal GC synthesis. Mice 
were control treated or colitis was induced by 3% DSS in drinking water.  
(A and B) Histology of colon from control mice (A) or colitogenic mice (B) at 
day 9. (C and D) Time course of weight loss (C) and colon length (D) in  
control- and DSS-treated mice. Means ± SD are shown (n = 5 per group).  
(E and F) Expression of TNF (E) and IFN- (F) in control- and DSS-treated mice 
at day 7. Means ± SD are shown (n = 5 per group). (G and H) Expression of 
the steroidogenic enzymes CYP11A1 (G) and CYP11B1 (H) in control-treated 
and colitogenic mice at day 7. Mean and individual values of 6–10 mice per 
group are shown. (I) Time course of GC synthesis in colonic organ cultures 
of DSS-treated mice. Mean values and individual values of two to six mice 
per time point are shown. *, P < 0.05; **, P < 0.01; ***, P < 0.005. Pooled data 
are from three independent experiments. Bars, 100 µm.1060 TNF drives intestinal steroidogenesis | Noti et al.
in these animal models was the induction of TNF expression. 
We thus postulated that TNF may represent an important key 
factor in the regulation of colonic GC synthesis.
The TNF dependency has been well characterized for 
TNBS-induced colitis (Neurath et al., 1997; Ebach et al., 
2005). Although administration of TNBS into wild-type 
animals promoted intestinal inflammation (Fig. 2, B and C), 
TNF-deficient mice did not develop colitis and showed no 
induction of colonic GC synthesis (Fig. S1). These data sup-
port the notion that TNF and associated inflammation may 
be required for colitis-induced intestinal GC synthesis.
In contrast to the TNBS model, DSS-induced colitis pro-
ceeds in a TNF-independent manner (Fig. 4 A; Naito et al., 
2003). Interestingly, TNF even seems to have a protective 
effect in DSS colitis, as absence of TNF leads to an exacerba-
tion and acceleration of the disease. This is illustrated by 
increased weight loss of TNF-deficient mice (Fig. 4 A). Fur-
thermore, significantly higher levels of myeloperoxidase 
(MPO) activity were observed in the colonic tissue of TNF-
deficient compared with wild-type mice (Fig. 4 B), indicating 
a stronger infiltration of the affected tissue with neutrophilic 
granulocytes. The alteration of disease progression was also 
paralleled by a reduction in IFN- expression (Fig. 4 C) and 
an increase in IL-4 expression (Fig. 4 D), indicative of a shift 
from a Th1 to a Th2 response.
Remarkably, although inflammation and associated weight 
loss were accelerated in TNF-deficient mice, colonic steroido-
genesis was drastically reduced. Although DSS induced a dra-
matic increase in the expression of CYP11A1 and CYP11B1 
and associated colonic GC synthesis in wild-type animals, al-
most no induction of these steroidogenic enzymes and steroido-
genesis was observed in TNF-deficient mice (Fig. 4, E and F), 
despite  the  pronounced  induction  of  colonic  inflammation. 
These data indicate that TNF has an important and unique role 
in the induction of colitis-associated intestinal GC synthesis.
TNF is critical for the induction of intestinal steroidogenesis
To further define the general importance of TNF in the in-
duction of intestinal GC synthesis, we assessed the induction 
of CYP11B1 and corticosterone synthesis in wild-type and 
TNF-deficient mice after injection of anti-CD3 antibodies, 
which were previously shown to be a potent inducer of in-
testinal GC synthesis (Cima et al., 2004; Mueller et al., 2006). 
As shown in Fig. 5 (A and B), absence of TNF resulted in a 
significant reduction of CYP11B1 expression and corticoste-
rone synthesis in colonic organ cultures in response to in vivo 
T cell activation, demonstrating that TNF represents a more 
general trigger of extraadrenal GC synthesis in the intestinal 
epithelium. This was confirmed by i.p. injection of recombi-
nant TNF, which led to a significant increase in CYP11B1 
expression (Fig. 5 D) and intestinal GC synthesis (Fig. 5 C).
TNF seemed to directly target the intestinal epithelium, 
as treatment of the young adult mouse colonocyte (YAMC) 
epithelial cell line (Whitehead et al., 1993) resulted in a time- 
dependent degradation of IB (Fig. 5 E), indicating TNF re-
sponsiveness, and a dose-dependent induction of CYP11B1 
expression (Fig. 5 F). Interestingly, TNF-induced CYP11B1 
expression was blockable by the proteosome and NF-B acti-
vation inhibitor lactacystin but not by c-Jun N-terminal kinase 
Figure 2.  TNBS-induced Th1 colitis and intestinal GC synthesis.  
(A and B) Histology of control- (A) and TNBS-treated (B) mice at day 3.  
(C and D) Time course of weight loss (C) and colon length (D) in control- and 
TNBS-treated mice. Means ± SD are shown (n = 5 per group). (E and F) Ex-
pression of TNF (E) and IFN- (F) in control- and TNBS-treated mice at day 2. 
Means ± SD are shown (n = 5 per group). (G and H) Expression of the ste-
roidogenic enzymes CYP11A1 (G) and CYP11B1 (H) in control- and TNBS-
treated mice at day 2. Mean and individual values of five to six mice per 
group are shown. (I and J) Time course of GC synthesis in colonic organ cul-
tures of TNBS- (I) and control-treated mice (J). Mean and individual values of 
two to six mice per time point are shown. **, P < 0.01; ***, P < 0.005. Pooled 
data are from three independent experiments. Bars, 100 µm.JEM VOL. 207, May 10, 2010 
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The TNF-mediated induction of CYP11A1 and CYP11B1 
mRNA expression could also be reproduced in ex vivo–
cultured primary colonic epithelial cells (Fig. 5 H and Fig. S2).
Administration of TNF during oxazolone colitis restores 
intestinal GC synthesis and ameliorates disease
Our data described in the previous section indicated that TNF 
is critical for induction of intestinal GCs during experimental 
(JNK) inhibitors or mitogen-activated protein (MAP) kinase 
inhibitors, suggesting a role for NF-B activation in TNF- 
induced steroidogenesis in intestinal epithelial cells (Fig. 5 G). 
Figure 3.  Oxazolone-induced Th2 colitis and intestinal GC synthesis. 
(A and B) Histology of control- (A) and oxazolone-treated (B) mice at day 3. 
(C and D) Time course of weight loss (C) and colon length (D) in control-  
and oxazolone-treated mice. Means ± SD are shown (n = 5 per group).  
(E and F) Expression of TNF (E) and IL-4 (F) in control- and oxazolone-treated 
mice at day 2. Means ± SD are shown (n = 5 per group). (G and H) Expression 
of the steroidogenic enzymes CYP11A1 (G) and CYP11B1 (H) in control- and 
oxazolone-treated mice at day 2. Mean and individual values of five to eight 
mice per group are shown. (I and J) Time course of GC synthesis in colonic 
organ cultures of oxazolone- (I) and control-treated mice (J). Mean and indi-
vidual values of three to five mice per time point are shown. *, P < 0.05. Pooled 
data are from three independent experiments. ns, not significant. Bars, 100 µm.
Figure 4.  TNF is required for DSS colitis–induced GC synthesis. 
(A) Kinetic of weight loss in control- or DSS-treated wild-type (TNF+/+) or 
TNF/ mice. (B) MPO activity in colonic tissue from control- or DSS-
treated TNF+/+ or TNF/ mice. (C and D) Expression of IFN- (C) and IL-4 
(D) in control or colitogenic mice. Means ± SD of five mice per group are 
shown. (E and F) Expression of CYP11A1 (E) and CYP11B1 (F) in colonic 
tissue from control- or DSS-treated TNF+/+ or TNF/ mice at day 6. Mean 
and individual values of 4–10 mice per group are shown. *, P < 0.05; **,  
P < 0.01; ***, P < 0.005. (G and H) Kinetic of corticosterone synthesis in 
colonic tissue from DSS-treated TNF+/+ and TNF/ mice. Mean and  
individual values of three to four mice per time point are shown. One 
typical experiment out of two is shown.1062 TNF drives intestinal steroidogenesis | Noti et al.
colitis. Furthermore, the failure to induce TNF during oxazo-
lone colitis may be the reason for lack of colonic GC synthesis. 
To test whether administration of TNF could restore colonic 
Figure 5.  Role of TNF in anti-CD3–induced intestinal GC synthe-
sis. (A) TNF+/+ or TNF/ mice were injected i.p. with PBS control or anti-
CD3 antibody, and corticosterone production in colonic organ cultures 
was assessed. (B) CYP11B1 expression in colonic tissue from PBS- and 
anti-CD3–treated TNF+/+ or TNF/ mice. (C) Corticosterone synthesis in 
colonic organ culture from control-treated (PBS) mice or mice that were 
injected with recombinant TNF or anti-CD3 antibody. (D) Mice were 
treated as in C and CYP11B1 expression was measured in colonic tissue. 
Means ± SD from five mice per group are shown. *, P < 0.05; **, P < 0.01. 
(E) YAMCs were stimulated with TNF for the indicated time points and IB 
degradation was assessed by Western blotting. (F) Cells were stimulated 
with increasing concentrations of TNF for 6 h and CYP11B1 expression 
was analyzed. (G) YAMCs were pretreated with medium control, lactacys-
tin, JNK inhibitor 1, or the MAP kinase inhibitor U0126 before stimulation 
with TNF. CYP11B1 expression was analyzed after 6 h by real-time PCR. 
(H) Primary colonic epithelial cells were stimulated for 4 h with TNF, and 
CYP11B1 mRNA expression levels were measured by quantitative PCR. 
One typical experiment out of three is shown.
GC synthesis, oxazolone colitis was induced and mice were 
further treated daily with PBS or mouse TNF. Although TNF 
has been previously described to induce cachexia (Haslett, 
1998), TNF injection into control mice did not substantially 
alter the body weight during the observation time (Fig. 6 D). 
In marked contrast, however, daily treatment of colitogenic 
mice with TNF significantly reduced oxazolone-induced 
body weight loss, suggesting disease amelioration. This find-
ing was further substantiated by reduced signs of inflamma-
tion in colonic tissue (Fig. 6, A and B), reduced colitis score 
(Fig. 6 C), and colon shortening (Fig. 6 E) in TNF-treated 
colitogenic mice compared with mice receiving oxazolone 
only. Interestingly, we also observed a strong increase in TNF 
expression in oxazolone plus TNF–treated mice, whereas only 
baseline levels were seen in mice treated with oxazolone only 
(Fig. 6 G). In contrast, TNF treatment substantially reduced 
IL-4 expression typically seen in the oxazolone-induced Th2–
type colitis (Fig. 6 F). In agreement with a critical role of TNF 
in the induction of colonic GC synthesis, we observed in-
creased CYP11A1 (Fig. 6 H) and CYP11B1 (Fig. 6 I) ex-
pression, and associated GC synthesis (Fig. 6 J) in colonic 
tissue from mice treated with TNF or TNF plus oxazolone. 
Thus, TNF treatment restores colonic GC synthesis and 
ameliorates oxazolone colitis.
Inhibition of intestinal GC synthesis abrogates the 
antiinflammatory effect of TNF
To prove that the therapeutic effect of TNF in oxazolone- 
induced colitis is mediated via the induction of colonic GC 
synthesis, we aimed at blocking TNF-induced GC synthesis 
by metyrapone. Although therapeutic administration of TNF 
restored colonic GC synthesis, inhibition of 11-hydroxylase 
by in vivo treatment with metyrapone resulted in significantly 
reduced intestinal corticosterone synthesis. The inhibition of 
TNF-induced colonic GC synthesis by metyrapone was paral-
leled by increased weight loss and histological colitis score, 
indicating that inhibition of colonic GC synthesis abrogates 
the observed antiinflammatory therapeutic effect of TNF in 
oxazolone-induced colitis (Fig. 7). These findings confirm 
that the antiinflammatory activity of TNF in oxazolone-
induced colitis is mediated via the induction of colonic GC 
synthesis. A comparable protective effect of therapeutic 
administration  of  TNF  was  also  found  in  the  DSS  colitis 
model. TNF-treated mice showed reduced weight loss and 
neutrophil infiltration, paralleled by increased colonic ste-
roidogenesis (Fig. S3).
DISCUSSION
TNF is an important initiator cytokine of inflammatory re-
sponses. Thus, TNF has been identified as a major therapeutic 
target in different inflammatory diseases. The importance of 
TNF in IBD has been demonstrated in a variety of colitis 
models (Neurath et al., 1997; Corazza et al., 1999, 2004). Con-
sequently, neutralization of TNF by antibodies or soluble 
receptor, or TNF deficiency significantly attenuates the 
pathogenesis of experimental IBD. Similarly, administration JEM VOL. 207, May 10, 2010 
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Figure 6.  Administration of TNF restores intestinal GC synthesis 
and protects from oxazolone-induced colitis. Colitis was induced by 
intrarectal administration of ethanol control or oxazolone. Mice were 
then treated daily with buffer control or TNF. (A and B) Histology of  
colonic tissue of mice with oxazolone colitis (A) or oxazolone colitis 
treated with TNF. (C) Analysis of histological alterations (colitis score) 
in the colonic tissue of mice treated with oxazolone and/or TNF.  
(D and E) Time course of weight loss (D) and colon length (E) in control- 
and oxazolone-treated mice with or without TNF therapy. (F and G) IL-4 
(F) and TNF (G) mRNA expression in colonic tissue. (H and I) Expression 
of the steroidogenic enzymes CYP11A1 (H) and CYP11B1 (I). (J) GC syn-
thesis in ex vivo colonic organ cultures. All parameters were measured at 
day 2. Symbols represent values of individual mice; horizontal bars indi-
cate mean values. In some experiments, means ± SD are shown (n = 4–7 
mice per group). *, P < 0.05; **, P < 0.01; ***, P < 0.005. One typical ex-
periment out of three is shown. Bars, 100 µm.
of humanized anti-TNF antibody (infliximab) has astonish-
ing therapeutic effects in IBD patients (Hanauer and Present, 
2003). As chronic inflammation may be one of the underlying 
causes of cancer, anti-TNF also has preventive effects on the 
development of colitis-associated colon cancer (Wilson, 2008).
Apart from these well-established proinflammatory activ-
ities, there is increasing evidence for antiinflammatory prop-
erties of TNF. At least in part, these antiinflammatory effects 
of TNF may be attributed to apoptosis-inducing and/or 
apoptosis-modulating activities in immune cells. Although 
TNF-induced apoptosis in intestinal epithelial cells further 
compromises the epithelial barrier integrity and accelerates 
intestinal inflammatory responses by permitting constant 
stimulation of immune cells with luminal antigens and fac-
tors, TNF-induced apoptosis in immune cells may help to 
terminate and/or control inflammation. Interestingly, differ-
ential signals via TNFR1 or 2 are at least in part responsible 
for this dual role of TNF in inflammatory processes. In line 
with the differential signaling of TNFRs in immune cells is 
the observation that TNBS colitis is more severe in TNFR1-
deficient mice, whereas it is significantly reduced in TNFR2-
deficient animals (Holtmann et al., 2002; Ebach et al., 2005). 
Similarly, neutralization of TNF (Kojouharoff et al., 1997) or 
absence of TNF (our own findings; Naito et al., 2003) exac-
erbates acute DSS-induced colitis. Often, the proinflamma-
tory action of TNF is critical for the initiation of disease, 
whereas its antiinflammatory function helps to resolve the 
disease. This dual role of TNF has also been recently demon-
strated in the pathogenesis of experimental autoimmune en-
cephalomyelitis (Kassiotis and Kollias, 2001).
In this paper, we report on a so far unrecognized role of 
TNF in (negatively) controlling acute intestinal immune re-
sponses. We identified TNF as a critical factor in the induc-
tion of local GC synthesis during the course of experimental 
colitis. DSS and TNBS, both promoting a Th1-type inflam-
mation including a strong production of TNF, induced a pro-
nounced and transient GC synthesis in the colon. In marked 
contrast, the Th2 cytokine–dominated inflammation induced 
by oxazolone failed to induce TNF and intestinal GC synthe-
sis. Remarkably, therapeutic administration of TNF was able 
to restore colonic GC synthesis and resulted in an overall im-
provement of all clinical colitis parameters. Critically, inhibi-
tion of colonic GC synthesis by metyrapone abrogated the 
therapeutic effect of TNF, indicating that the antiinflamma-
tory effect of TNF in experimental colitis is mediated via the 
induction of colonic GC synthesis. Although the present pro-
tocol of therapeutic TNF administration only resulted in a 
partial improvement in oxazolone-induced colitis, these ex-
periments demonstrate that TNF is critical for the induction 
of intestinal GC synthesis, and that TNF-induced GCs have 
an antiinflammatory role in the regulation of experimental 
colitis. More optimized TNF-based treatments or selective 
engagement of further downstream signaling pathways leading 
to intestinal GC synthesis may result in even better therapeutic 
effects. Importantly, although previously antiinflammatory   
effects of TNF have been attributed to its action on T cells, 1064 TNF drives intestinal steroidogenesis | Noti et al.
Figure 7.  Inhibition of intestinal GC synthe-
sis abrogates the antiinflammatory effect of 
TNF. Colitis was induced by intrarectal adminis-
tration of ethanol control or oxazolone. Mice were 
then treated daily with buffer control or TNF, and 
intestinal GC synthesis was blocked by administra-
tion of metyrapone. (A) Corticosterone synthesis 
in ex vivo colonic organ cultures. (B) Kinetic of 
body weight loss. (C) Analysis of histological  
alterations (colitis score) in colonic tissue of mice 
treated with ethanol as control, oxazolone alone, 
oxazolone + TNF, and oxazolone + TNF + metyra-
pone. Means ± SD are shown (n = 6–9 animals  
per group). **, P < 0.01; ***, P < 0.005. One typical 
experiment out of three is shown.
i.e., modulation of apoptosis sensitivity, we now provide evi-
dence for an alternative pathway via the induction of immuno-
regulatory GCs in intestinal epithelial cells.
We have previously demonstrated the relevance of intes-
tinal GC synthesis in the regulation of local immune cells. 
For example, lack of intestinal GC production resulted in 
stronger activation of virus-specific intestinal T cells (Cima   
et al., 2004). Colonic GC synthesis likely also contributes to 
the regulation of IBD. Indirect proof for this idea is seen in 
DSS colitis, where absence of TNF results in a lack of colonic 
GC synthesis and exacerbation of disease (Naito et al., 2003). 
Further support for a role for intestinal GC synthesis in the 
regulation of IBD comes from a recent report by Coste et al. 
(2007). We recently identified the nuclear receptor and tran-
scription factor LRH-1 as a critical regulator of intestinal GC 
synthesis (Mueller et al., 2006, 2007). Consequently, it was 
observed that LRH-1–deficient mice are more susceptible 
to DSS- and TNBS-induced colitis, supporting a role of   
LRH-1–regulated GC synthesis in experimental models of 
mucosal inflammation (Coste et al., 2007). The transient   
nature of colitis-induced GC synthesis mentioned above and 
the failure of intestinal GCs to completely control local in-
flammation may also be caused by the selective loss of LRH-1–
expressing and GC-producing cells in the intestinal crypts. 
In fact, during IBD the intestinal crypts are characterized by 
excessive apoptosis, promoting epithelial barrier disruption and 
access to proinflammatory factors in the lumen, but also im-
paired epithelial barrier recovery and reduced GC synthesis. 
It is of interest to note that LRH-1 is not only critically in-
volved in the regulation of intestinal GC synthesis, but is also 
an important regulator of intestinal crypt cell proliferation 
and thereby intestinal epithelial cell renewal (Botrugno et al., 
2004). Furthermore, GCs promote tight junction forma-
tion in intestinal epithelial cells and thereby contribute to the 
maintenance of intestinal epithelial barrier function. Thus, 
LRH-1 likely represents a critical regulator of intestinal tissue 
integrity via the regulation of epithelial cell integrity and in-
testinal immune homeostasis. Defects in LRH-1–induced 
epithelial layer integrity and intestinal GC synthesis may fur-
ther exacerbate the local inflammation and course of the dis-
ease by promoting a vicious cycle.
In summary, we provide first-time evidence for a novel 
antiinflammatory role of TNF in experimental colitis via the 
local production of immunoregulatory GCs. Although we de-
fined an antiinflammatory role of TNF and local GC synthesis 
specifically in acute models of intestinal inflammation, it will 
be interesting to determine whether the same applies also for 
chronic types of intestinal inflammation, more closely related 
to Crohn’s disease and ulcerative colitis in humans. None-
theless, the use of the three acute models of experimental 
colitis strongly support the idea that intestinal GC synthesis is 
an important negative regulatory feedback mechanism con-
trolling intestinal immune responses and inflammation. Fur-
thermore, they illustrate that TNF has a Janus-like pro- and 
antiinflammatory activity in the regulation of intestinal in-
flammation. The identification of critical signaling molecules 
regulating the local synthesis of antiinflammatory GCs may 
represent interesting novel targets in the treatment of IBD.
MATERIALS AND METHODS
Cells and reagents
YAMCs (provided by R.H. Whitehead, Vanderbilt University, Nashville, 
TN) have been described previously (Whitehead et al., 1993). YAMCs 
were cultured in RPMI 1640 supplemented with 5% FCS, 2 mM l-gluta-
mine, 1 mg/ml insulin, 0.55 mg/ml human transferrin, 0.5 µg/ml sodium 
selenite, 5 U/ml of mouse recombinant IFN- (PeproTech), and 50 µg/ml 
gentamycin, and were grown at the permissive temperature of 33°C and 
5% CO2. Lactacystin, JNK inhibitor 1, and MAP kinase inhibitor U0126 
were obtained from Enzo Life Sciences, Inc. Primary intestinal crypt cells 
from large and small bowels were isolated as previously described (Sato   
et al., 2009).
Animals
Animal experiments were performed in compliance with Swiss laws and guide-
lines, and were approved by the animal experimentation committee of the 
State of Bern. Wild-type and TNF-deficient (Corazza et al., 2004) C57BL/6 
mice were bred and kept in the Central Animal Facility of the Department of 
Medicine, University of Bern, and group-housed with free access to food and 
tap water. Mice were used for experiments between 7–11 wk of age.
Mouse models of colitis
DSS-induced colitis. DSS colitis was induced by administration of 3% 
(wt/vol) DSS (reagent-grade DSS salt; molecular mass = 36–50 kD; MP 
Biomedicals) in normal drinking water for 5 d, followed by a 4-d normal 
water consumption.
TNBS-induced colitis. Animals were fasted for 24 h and anesthetized by 
a subcutaneous injection of xylasine/ketamine upon intrarectal administra-
tion of 60 µl TNBS (150 mg/kg; Fluka) dissolved in 50% ethanol. Under the 
same conditions, control mice received 60 µl of 50% ethanol. Solutions were JEM VOL. 207, May 10, 2010 
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administered via a 3.5F catheter equipped with a 1-ml syringe. The tip of the 
catheter was inserted 4 cm proximal to the anal verge. To ensure distribution 
of TNBS within the entire colon, animals were held in a vertical position for 
30 s after injection.
Oxazolone-induced  colitis.  Mice  were  presensitized  by  epicutanous   
application  of  3%  oxazolone  (4-ethoxymethylene-2-phenyl-2-oxazolin- 
5-one; Sigma-Aldrich) in 100% ethanol in a volume of 150 µl at day 7. 
Animals were fasted and anesthetized as described in the previous section, 
and received an intrarectal administration of 100 µl of 1% oxazolone in 50% 
ethanol as described in the previous section. Control mice received 100 µl of 
50% ethanol under the same conditions.
Body weight loss and rectal bleeding of all animals were monitored dur-
ing the experiments. Mice were killed at different time points by CO2  
asphyxiation and blood was sampled. Plasma was obtained by centrifugation 
at 2,000 g for 10 min at 4°C and stored at 80°C until analysis. Large bowels 
were removed, measured, and snap frozen or fixed in 4% paraformaldehyde 
for  further  biochemical  and  histological  analysis.  Histological  analysis  of   
colonic inflammation was performed as previously described (colitis score) 
with a minimal score of 0 and a maximum score of 15 (Corazza et al., 1999, 
2004). Adrenal glands were collected as positive controls for steroidogenic 
enzyme expression and corticosterone synthesis.
In vivo administration of anti-CD3 and TNF
In some experiments, intestinal GC synthesis was induced by i.p. injection 
of 20 µg anti-CD3 antibody, as described previously (Cima et al., 2004), or 
1 µg of recombinant mouse TNF (PreproTech). After 3 h, mice were eutha-
nized and colonic tissue was isolated for analysis of GC synthesis and expres-
sion of steroidogenic enzymes.
During oxazolone-induced colitis, PBS control or TNF (1 µg/dose) 
were administered daily i.p. at days 0.5, 1, and 2 before analysis of GC 
synthesis  and  intestinal  inflammation.  In  some  experiments,  intestinal 
GC synthesis was blocked by i.p. administration of 11-hydroxylase and the 
GC synthesis inhibitor metyrapone (200 mg/kg of body weight; Sigma-
Aldrich) twice daily at days –1, 0, 1, and 2.
Detection of corticosterone synthesis in intestinal organ cultures
The entire large intestine was opened longitudinally and cut into 5-mm-
long pieces, washed extensively in PBS/2% charcoal-stripped horse serum 
(SHS), and incubated for 10 min at 4°C in PBS/2% SHS containing 1 mM 
1,4-dithiothreitol to remove excess mucus. After an additional washing step, 
tissue pieces were randomly distributed to 2 wells of a 24-well plate and cul-
tured in 10% charcoal-stripped IMDM in the presence or absence of 200 
µg/ml of the GC synthesis inhibitor metyrapone (Sigma-Aldrich). As posi-
tive control for GC synthesis, the adrenal glands were cut in half and incu-
bated as described. After 6 h of incubation at 37°C, cell-free supernatant was 
harvested and corticosterone concentration was measured using a radioim-
munoassay. Results are expressed as nanograms of corticosterone per gram of 
tissue and are shown as the difference of samples cultured without metyra-
pone and samples cultured with metyrapone (metyrapone-blockable corti-
costerone synthesis) to correct for variable contamination with serum GCs 
(Mueller et al., 2006).
Real-time PCR
One third of the entire colons of colitogenic and control animals was homog-
enized and lysed in TRI-reagent (Sigma-Aldrich) for further RNA isolation. 
RNA was DNase-treated and reverse transcribed using a high capacity RT 
kit (Applied Biosystems). RT-PCR was performed in the 7500 Real-Time 
PCR  System  (Applied  Biosystems)  using  Quantitect  primer  assays  for  the   
steroidogenic enzymes CYP11A1 and CYP11B1, and the cytokines IL-4, TNF, 
and IFN-. GAPDH or villin were used to normalize expression levels.
In some experiments, YAMCs were pretreated with the proteosome 
and NF-B inhibitor lactacystin, JNK inhibitor 1, or the MAP kinase inhibi-
tor U0126 (all at 1 µM) before stimulation with 3 ng/ml TNF and analysis 
of CYP11B1 induction.
NF-B activation assay
YAMCs were incubated for different time points with 3 ng/ml TNF. Total 
protein lysates were extracted after standard procedures. After blotting, 
nitrocellulose membranes were incubated overnight at 4°C with a rabbit 
polyclonal IB antibody, washed, and incubated for 1 h at room tem-
perature with a goat anti–rabbit peroxidase conjugate secondary antibody. 
Equal protein loading was confirmed by detection of -tubulin.
MPO activity
Neutrophil infiltration in control and colitogenic animals was quantified by 
measuring the activity of MPO in colonic homogenates, as described previ-
ously (Pfister et al., 2000). In brief, 50 mg of tissue was resuspended in   
50 mM of potassium phosphate buffer containing 0.5% hexadecyltrimethyl-
ammonium bromide, and homogenized subsequently. The mixture was 
submitted to three cycles of freeze-thawing, followed by sonication for 20 s 
and centrifugation for 30 min. MPO activity was measured by incubating 
the supernatants with 20 mg/ml O-dianisidine dihydrochloride and 20 mM 
hydrogen peroxide. The reaction was terminated by the addition of 2%   
sodium azide. Optical density was read at 450 nm. Samples were measured 
in triplicates and are expressed as units per gram of tissue. All reagents were 
purchased from Sigma-Aldrich.
Statistics
Results are expressed as means ± SEM. Alternatively, values of individual 
samples and the mean of the group are shown. Differences between groups 
were analyzed by the unpaired Student’s t test. P < 0.05 was considered 
statistically significant.
Online supplemental material
Fig. S1 shows that TNF is required for TNBS-induced colonic inflammation 
as well as GC synthesis. Fig. S2 describes the effect of TNF on expression of 
steroidogenic enzymes in primary intestinal epithelial cells. Fig. S3 describes the 
therapeutic effects of TNF in DSS-induced colitis. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20090849/DC1.
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